LEAP2 and neoplasm: Patients with a larger tumor burden—defined as a primary tumor size ≥ 2.5 cm, the presence of multiple pancreatic tumors, or tumor metastases—showed a trend toward higher serum LEAP2 levels compared with those with a lower tumor burden (median 30.9 ng/mL, range 2.02-79.1 ng/mL vs. 20.2 ng/mL, range 14.28-70.66 ng/mL; P = 0.118; Supplementary Figure 6).